Introduction: Renal safety is an important factor in selecting the most appropriate
INTRODUCTION
Hepatitis B virus (HBV) infection is a major global public health concern. Evidence from available data suggest that an estimated 240 million individuals are chronically infected with HBV worldwide, and approximately one million die from chronic hepatitis B (CHB)-related diseases every year [1, 2] .
Previous studies have described an association between CHB and chronic kidney disease (CKD) German centers concluded that treatment of HBV monoinfection with adefovir (n = 32), entecavir (n = 32), lamivudine (n = 36), or tenofovir (n = 37) resulted in a mild decrease in renal function [11] [12] [13] . Therefore, renal safety is an important factor in selecting the most appropriate NA treatment for patients with CHB, particularly in those who are at risk for renal impairment. Recent literature suggests that telbivudine is associated with improvement in renal function in patients with CHB. However, there is a lack of systematic evidence base regarding the comparison of renal function associated with NAs. Hence, it is important to collate all available evidence and summarize the data regarding the effect of various NAs on renal function in patients with CHB, either as monotherapy or combination therapy. The aim of the current systematic literature review (SLR) and a network meta-analysis (NMA) is to assess renal function associated with telbivudine treatment compared to other NAs in patients with CHB.
METHODS
This SLR followed a standard, systematic review methodology endorsed by the Cochrane Collaboration [14] and the National Institute for Health and Care Excellence (NICE) in the UK [15] . The SLR was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [16] .
Inclusion and Exclusion Criteria

Inclusion Criteria
All randomized controlled trials (RCTs) and observational studies published in the English language, conducted in patients with CHB regardless of their hepatitis B envelope antigen (HBeAg) status, were included. Studies evaluating interventions/comparators (either monotherapy or combination therapies) such as adefovir, entecavir, lamivudine, telbivudine, tenofovir, and placebo with reported eGFR outcomes (either absolute change or percentage improvement from baseline) were included.
Exclusion Criteria
Animal and in vitro studies; studies in patients co-infected with human immunodeficiency virus, hepatitis C virus, or hepatitis D virus; and studies that did not report interventions, comparators, and outcomes of interest were excluded. In addition, review articles, editorials, case reports, case series, and economic evaluations were excluded.
Search Strategy
Comprehensive literature searches were conducted by searching electronic databases (Medline, Medline In-Process, Embase, and the Cochrane Library) from the inception of each database to July 2015. The multistring search strategy was based on a combination of medical subject headings (MeSH) and keywords including ''adefovir'', ''entecavir'', ''lamivudine'', ''telbivudine'', ''tenofovir'', ''chronic hepatitis B'', ''hepatitis B'', ''chronic kidney disease'', ''CKD'', ''glomerular filtration rate'', and ''eGFR''. Reference lists of any relevant studies, recent systematic reviews, or meta-analyses were also searched for any additional studies to add to the evidence base.
First-Level Screening of Citations
All the publications retrieved from the literature search were screened based on the title and abstract provided with each citation. The inclusion/exclusion criteria were uniformly applied across all the publications. Two independent reviewers screened the retrieved abstracts, and a third independent reviewer reconciled any discrepancies between them.
Publications that did not meet the eligibility criteria were excluded, and the reasons for exclusion were documented. Subsequently, full-text copies of all the publications that met the eligibility criteria were downloaded.
Second-Level Screening of Citations
The inclusion and exclusion criteria were uniformly applied across all the full-text publications. The same two reviewers screened all the manuscripts, and the third independent reviewer reconciled any discrepancies between them. Publications that did not meet the eligibility criteria were excluded, and the reasons for exclusion were documented. Publications that met the eligibility criteria were subjected to data extraction.
Data Extraction
The same reviewers extracted data independently using a prespecified data extraction template, and as before, the third independent reviewer resolved any discrepancies. Data were extracted from various information sources in a study, such as objectives, methods, inclusion and exclusion criteria, baseline demographic and clinical characteristics, interventions, efficacy outcomes, and conclusions. Studies with multiple publications were linked to one another and extracted as a single study.
Critical Appraisal (Quality Assessment)
Each included study was assessed for methodological quality (internal and external validity). RCTs that met the eligibility criteria for review were critically appraised for quality based on the NICE recommendations [15] . All included observational studies were critically appraised for quality based on the Downs and Black checklist [17] .
Assessment of Endpoints
The primary endpoint of the analysis was change in eGFR from baseline. Most of the studies reported the renal function outcomes at 48-52 weeks. There were few studies reporting renal function outcomes at 2-year follow-up. Hence, the study endpoints were analyzed at a time point of 1 year (48-52 weeks). For studies that did not report change in eGFR from baseline, the change was calculated based on the reported baseline and endpoint eGFR values.
Network Meta-Analysis
The NMA was performed using statistical methods to combine data from various studies in order to obtain a coherent picture of treatment outcomes and compare various treatment options. performed to conduct the NMA, and only non-RCTs were found to be eligible. All non-RCTs were assumed comparable in terms of study design, and for studies with missing standard error (SE) values, SE was assumed to be 10% of the mean change in eGFR from baseline.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
Search Results
The results of the literature search are summarized in Fig. 1 . The search of the literature databases yielded 974 publications. Of these, 247 were duplicates due to an overlap of records across the searched databases. Following the initial screening of these citations, 110 potentially relevant publications were identified and 49 of them were included after a more detailed evaluation. Three publications were additionally identified through a bibliographic search of the relevant systematic reviews, yielding 40 studies from 52 publications for synthesis of evidence.
Study Characteristics
Of the 40 studies included, 20 were full-text publications and 20 were conference abstracts. In total, six RCTs and 34 observational studies were included (17 retrospective studies, 12
prospective studies, three non-RCTs, and one case-control study and cross-sectional study each). Of the 40 included studies, 35 had an active control group, and in the remaining five studies, NAs were compared with untreated Thirteen of the 40 studies were multicenter studies, whereas 16 studies had been conducted at a single center. In the remaining 11 studies, the study location was unclear. Overall, 90%
(36/40) of the studies were conducted in populations with mixed HBeAg status, whereas only three studies [21] [22] [23] enrolled
HBeAg-negative patients and one study [24] enrolled HBeAg-positive patients. The mean age among the included studies ranged from 34 [25] to 55 [26] years. Approximately 15% (6/40) of the included studies enrolled over 70% of the male population. Modification of Diet in Renal Disease (MDRD) was the most commonly used equation to measure eGFR among the included studies (see Table S1 in the online supplementary material).
Of the six RCTs that exhibited similarities among treatment groups in terms of baseline characteristics, two studies reported an adequate method of allocation concealment and two reported an adequate method of blinding for patients and caregivers. An adequate method of statistical analysis was reported in three studies. For the observational studies, the majority of relevant information was missing from the conference abstracts; the Downs and Black total scores ranged from 2 [27] to 18 [28] . Overall, the methodological quality of the included studies was adequate.
Trends for Changes in eGFR over Different Time Points Figure 2 shows the changes in eGFR over different time points across the included studies for entecavir, lamivudine, telbivudine, . Only a few studies had reported eGFR with adefovir at different time points; hence, a trend diagram could not be constructed.
However, eGFR decreased persistently with adefovir treatment. The annual eGFR decline from baseline was 5.62 mL/min (first year), 11.26 mL/min (second year; P = 0.0008 vs. baseline), and 13.72 mL/min (third year; P = 0.0005 vs.
baseline) [40] . The network diagram (Fig. 4) shows the full network of evidence of treatment regimens for changes in eGFR from baseline at the 1-year time point. Overall, NMA was feasible for 12 non-RCTs. Over the years, published literature has provided increasing evidence for the Fig. 3 Trends for eGFR changes from baseline at 1 year. The size of the bubble corresponds to the sample size for corresponding treatment. eGFR estimated glomerular filtration rate renoprotective effects of telbivudine [26, 30, 31, 38, 40] . The mechanism of eGFR improvement with telbivudine remains to be determined. Numerous studies have shown that the decline in eGFR associated with adefovir or tenofovir treatment is attributed to the activity of these drugs against human mitochondrial DNA (mtDNA) [34] . The proximal tubules are intrinsically susceptible to mitochondrial dysfunction because of limited anaerobic adenosine triphosphate (ATP)-generating capacity [41] . These NAs (adefovir and tenofovir) are primarily excreted in unchanged forms through urine; therefore, inhibition of renal c-mtDNA may affect renal function [42] .
A head-to-head cohort study compared the effects of various NAs on eGFR in Chinese patients with CHB [40] . The authors concluded that prolonged telbivudine therapy resulted in improvements in eGFR, whereas adefovir therapy was associated with a decrease in eGFR; moreover, lamivudine and entecavir did not significantly affect eGFR [40] . The European Association for the Study of the Liver (EASL) guidelines recommend that for patients at low function should be monitored every 3 months during the first year and every 6 months thereafter if there is no worsening. For patients at a high renal risk, renal function should be monitored every month for the first 3 months, every 3 months until the end of the first year, and every 6 months thereafter if there is no worsening [43] . Gane et al. [31] have reported the renoprotective effects of telbivudine in a comprehensive analysis of renal function by using a telbivudine clinical trial database. This study evaluated renal function, focusing on the 2-year data from the GLOBE study. The authors showed that renal function, as assessed by the three equations for eGFR (CG, MDRD, and CKD-EPI), improved in patients who received telbivudine, whereas those who received lamivudine experienced a decline in renal function. Furthermore, an extension study of the GLOBE trial showed that even patients previously treated with lamivudine benefited from the renoprotective effects of telbivudine, with an additional increase in their eGFR of approximately 10%. This study also reported that eGFR improvement was maintained during long-term (4-6 years) telbivudine treatment [31] . An open-label, 2-year extension study that assessed the safety and efficacy of long-term telbivudine treatment in 596 patients with CHB without genotypic resistance after 2 years of initial telbivudine treatment reported that telbivudine-treated patients showed a steady increase in eGFR over 2 years, which remained elevated for up to 4 years [44] .
Only one meta-analysis has been published in the literature that evaluated the renal safety [14] , and the NICE guidelines [15] . A well-defined protocol including comprehensive search strategy, eligibility criteria, and data points to be extracted was followed throughout the process. The analyses were performed using the Bayesian MCMC algorithm. Although the NMA was feasible only with non-RCTs, the data from RCTs consistently indicated that telbivudine was associated with improvement in renal function (see Table S3 in the online supplementary material).
Thus, results from both clinical trials and real-world studies strongly suggest that telbivudine is associated with improvements in renal function in patients with CHB, either alone or in combination with other NAs, and these improvements were observed in patients with both compensated liver disease as well as decompensated cirrhosis.
Further, the improvements in renal function were maintained for up to 6 years. Moreover, patients with mild renal impairment at baseline who were treated with telbivudine also experienced a consistent improvement in eGFR. Over the years, renal safety has emerged as an important treatment-related concern in NA-treated patients. Although viral resistance and adverse events due to NA treatment are key factors when selecting a particular therapy for CHB, the current findings suggest that telbivudine offers a more favorable renal safety profile compared to other NAs, which may make it the drug of choice for patients at risk for renal dysfunction.
CONCLUSION
This SLR and NMA provide evidence that telbivudine is associated with a significant improvement in renal function (eGFR) in patients with CHB, either alone or in combination with other NAs. 
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